Xilio Therapeutics (NASDAQ:XLO) Shares Up 1%

Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) traded up 1% during trading on Wednesday . The company traded as high as $1.11 and last traded at $1.06. 297,031 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,045,277 shares. The stock had previously closed at $1.05.

Xilio Therapeutics Trading Up 1.0 %

The company has a market capitalization of $36.54 million, a P/E ratio of -0.38 and a beta of -0.12. The business has a 50 day moving average price of $0.90 and a 200 day moving average price of $1.03.

Insider Buying and Selling

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. bought 485,250 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was acquired at an average cost of $0.76 per share, with a total value of $368,790.00. Following the purchase, the insider now owns 7,345,473 shares in the company, valued at $5,582,559.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC acquired a new stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned about 0.09% of Xilio Therapeutics at the end of the most recent quarter. Institutional investors own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.